tirzepatide class Day 3: Mounjaro (Tirzepatide – weekly injection) Class: Dual GLP-1 and GIP receptor agonist Avg Weight Loss: ~20% of baseline weight (SURMOUNT-1 trial) FDA Status: Approved for type 2 diabetes; Fast-tracked for Effect of tirzepatide on change
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Nov 15 - Nov 20




















![Official Store🇺🇸] Lmipki® NIDDK-Tirzepatide Nano Microneedle Patch](https://cdn.shopify.com/s/files/1/0280/7578/6318/files/6_3fe07cdf-07cb-488b-b9d3-4009028da07d.png?v=1748003207)





